Bulk Pharmaceutical API Sources for vismodegib

Bulk Pharmaceutical API Sources for vismodegib

Vendor	Vendor Homepage	Vendor Sku	API Url
Exclusive Chemistry Ltd		EC-000.2333
ChemMol		81410476
Amadis Chemical		A10467
Exclusive Chemistry Ltd		Vismodegib
ChemMol		97300794
Adooq BioScience		GDC-0449 - Selumetinib
Inhibitor 2		Vismodegib

VISMODEGIB BULK API SOURCING ANALYSIS

Last updated: February 19, 2026

EXECUTIVE SUMMARY

This report analyzes the bulk active pharmaceutical ingredient (API) sourcing landscape for Vismodegib, a hedgehog pathway inhibitor indicated for the treatment of basal cell carcinoma. Key findings include the identification of a limited number of established API manufacturers, the prevalence of patent protection influencing market entry, and the critical role of regulatory compliance in API procurement. The analysis details current production capabilities, potential supply chain risks, and strategic considerations for securing a reliable and cost-effective API supply.

WHAT IS VISMODEGIB AND ITS MARKET POSITION?

Vismodegib is an orally administered small molecule inhibitor of the hedgehog signaling pathway. It is primarily used for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) that has progressed on or is inappropriate for treatment with a hedgehog inhibitor, or with locally advanced BCC that has the potential to be problematic such as those in the orbital, facial, or ear structures, and for whom surgery or radiation therapy is not a suitable option.

The U.S. Food and Drug Administration (FDA) approved Vismodegib (Erivedge) in January 2012, and it was subsequently approved by the European Medicines Agency (EMA) in March 2013. The drug is manufactured by Genentech, a member of the Roche Group.

The market for Vismodegib is characterized by its specific indication for a subset of BCC patients. While BCC is the most common type of skin cancer, advanced or metastatic cases requiring systemic therapy are less prevalent than localized disease. This specificity limits the overall volume demand for Vismodegib API compared to blockbuster oncology drugs.

WHO ARE THE KEY VISMODEGIB API MANUFACTURERS?

The landscape of Vismodegib API manufacturers is currently limited, primarily due to the proprietary nature of its synthesis and patent protection. The originator company, Genentech/Roche, likely maintains internal manufacturing capabilities or works with highly trusted contract manufacturing organizations (CMOs) under strict quality agreements.

As of [Current Year], publicly identifiable independent manufacturers of Vismodegib bulk API are scarce. This is a common scenario for highly specific, patented oncology drugs where the originator controls production to ensure quality, intellectual property protection, and supply chain security.

Information on independent third-party manufacturers typically emerges closer to patent expiry or when generic competition is actively preparing for market entry. Due diligence for sourcing Vismodegib API should focus on:

• Originator Control: Direct engagement with Genentech/Roche or their designated CMOs.
• Emerging Generic API Suppliers: Monitoring for companies filing Paragraph IV certifications or initiating ANDA (Abbreviated New Drug Application) processes in the U.S., which often signals the imminent availability of generic API. These may include established API players with expertise in complex synthesis.
• Specialized CMOs: Identifying CMOs with demonstrated capabilities in synthesizing complex small molecules under cGMP (current Good Manufacturing Practice) conditions, who may be willing to undertake custom synthesis projects under license or post-patent.

WHAT ARE THE INTELLECTUAL PROPERTY CONSIDERATIONS FOR VISMODEGIB API?

Vismodegib's API production is significantly influenced by patent protection. The primary patents covering Vismodegib and its use are held by Genentech, Inc. and the Hoffmann-La Roche AG.

• Composition of Matter Patents: These patents cover the chemical structure of Vismodegib itself.
• Process Patents: These patents protect specific methods of synthesizing the Vismodegib molecule. Innovator companies often secure multiple process patents to create a layered IP barrier.
• Formulation Patents: While not directly API sourcing, these can influence the types of API required for specific drug product formulations.

Key patents to monitor include those listed in the FDA’s Orange Book for the U.S. market and their equivalents in other major regulatory jurisdictions.

Patent Number	Issue Date	Expiration Date (Approximate)	Description
US7,632,950	2009-12-15	2028-12-15	Composition of matter and method of use
US9,090,510	2015-07-28	2032-07-28	Polymorphic forms and synthesis processes
WO2008125927	2008-10-23	Varies (Est. 2028-2030)	International application covering composition and synthesis

Note: Patent expiration dates are subject to extensions, such as Patent Term Extension (PTE) in the U.S. and Supplementary Protection Certificates (SPCs) in Europe. Exact dates should be verified through official patent databases and legal counsel.

The existence of these patents restricts any party from manufacturing or selling Vismodegib API without a license from the patent holder until the relevant patents expire. Any new entrant seeking to produce generic Vismodegib API must navigate this IP landscape, either by waiting for patent expiry or by challenging existing patents.

WHAT ARE THE REGULATORY AND QUALITY REQUIREMENTS FOR VISMODEGIB API?

Procurement of Vismodegib API is governed by stringent regulatory and quality standards mandated by health authorities worldwide, including the FDA, EMA, and PMDA (Japan).

Key Regulatory and Quality Aspects:

1. cGMP Compliance: API manufacturers must operate under current Good Manufacturing Practices (cGMP). This involves robust quality management systems, validated manufacturing processes, strict environmental controls, and comprehensive documentation.
2. Drug Master File (DMF) / Active Substance Master File (ASMF): API suppliers typically submit a DMF (in the U.S.) or ASMF (in Europe) to regulatory agencies. This confidential document details the manufacturing process, quality control, and specifications of the API. Drug product manufacturers then reference this DMF/ASMF in their marketing authorization applications.
3. Impurity Profiling: Comprehensive identification, characterization, and control of process-related impurities and degradants are critical. Genotoxic impurities require particularly rigorous control.
4. Analytical Method Validation: All analytical methods used for testing the API must be fully validated according to ICH (International Council for Harmonisation) guidelines.
5. Stability Studies: Extensive stability data demonstrating the API’s shelf-life under defined storage conditions is required.
6. Supply Chain Security: Ensuring the integrity and traceability of the API throughout the supply chain, from raw material sourcing to final delivery, is paramount to prevent counterfeiting and contamination.
7. Site Inspections: Regulatory agencies conduct periodic inspections of API manufacturing facilities to ensure ongoing cGMP compliance. Drug product manufacturers are also responsible for qualifying their API suppliers, which often includes conducting their own audits.

Specific Considerations for Vismodegib:

• Chiral Purity: If Vismodegib possesses chiral centers, enantiomeric purity must be rigorously controlled.
• Polymorphism: Different crystalline forms (polymorphs) of Vismodegib can impact its dissolution rate and bioavailability. Control over the polymorphic form is often critical and may be covered by specific patents. Manufacturers must demonstrate consistent production of the desired polymorph.
• Residual Solvents: Control of residual solvents used during synthesis must meet ICH Q3C guidelines.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS?

The Vismodegib API supply chain, like that for many specialized pharmaceuticals, faces several inherent risks:

1. Limited Supplier Base: As noted, the current scarcity of independent Vismodegib API manufacturers presents a significant risk. Over-reliance on a single or very few suppliers can lead to supply disruptions due to production issues, quality failures, or geopolitical events.
2. Intellectual Property Challenges: Litigation or challenges to existing Vismodegib patents can create uncertainty regarding future market access for generic API manufacturers. Conversely, successful patent challenges could lead to a rapid influx of new suppliers, potentially impacting pricing and quality.
3. Raw Material Dependency: The synthesis of complex molecules like Vismodegib relies on a chain of precursor chemicals and reagents. Disruptions in the supply of any critical raw material, especially those sourced from a limited number of global suppliers, can halt API production.
4. Geopolitical Instability and Trade Disputes: API manufacturing is often concentrated in specific regions. Geopolitical events, trade wars, or export restrictions can severely disrupt the flow of materials and finished API.
5. Regulatory Scrutiny and Changes: Evolving regulatory requirements for API manufacturing and quality can necessitate costly process modifications or facility upgrades, potentially impacting supplier capacity and cost.
6. Quality Failures and Recalls: Any lapse in cGMP compliance, leading to a product recall or manufacturing halt, would have immediate and severe consequences for drug product supply.
7. Capacity Constraints: As demand for Vismodegib fluctuates or as generic competition emerges, existing manufacturing capacity may become a bottleneck, leading to longer lead times and potential shortages.

STRATEGIC IMPLICATIONS FOR API SOURCING

For companies involved in the development or manufacturing of Vismodegib drug products, strategic sourcing of the API is critical. Key considerations include:

1. Dual Sourcing Strategy: Where possible, establishing relationships with at least two qualified API suppliers is a cornerstone of risk mitigation. This requires significant upfront investment in supplier qualification and auditing.
2. Early Engagement with Originator/Licensees: For existing drug products, understanding the supply arrangements with Genentech/Roche is the first step. If considering generic entry, early engagement with potential API suppliers who are actively preparing for market entry is crucial.
3. Robust Supplier Qualification: The qualification process must be rigorous, extending beyond initial audits to include ongoing performance monitoring, quality agreements, and clear communication channels. This includes assessing the supplier’s financial stability and business continuity plans.
4. Intellectual Property Due Diligence: For any potential generic API source, a thorough assessment of the IP landscape and freedom-to-operate opinions from legal counsel is essential to avoid infringement.
5. Long-Term Supply Agreements: Negotiating secure, long-term supply agreements with favorable terms regarding pricing, volume commitments, and lead times can provide stability.
6. Geographic Diversification of Suppliers: If multiple qualified suppliers exist, considering geographical diversification can reduce exposure to regional risks.
7. Understanding Raw Material Supply Chain: Investigate the upstream supply chain for critical raw materials used in Vismodegib API synthesis to identify potential vulnerabilities.
8. Technological Assessment: Evaluate the synthesis process of potential API suppliers. Innovative or more efficient synthesis routes may offer cost advantages or overcome specific patent barriers.

KEY TAKEAWAYS

• The Vismodegib API market is currently characterized by limited suppliers, largely due to patent protection and originator control.
• Intellectual property, particularly composition of matter and process patents, is the primary barrier to entry for new API manufacturers.
• Strict adherence to cGMP, robust impurity profiling, and comprehensive analytical validation are non-negotiable regulatory requirements.
• Supply chain risks include limited supplier diversification, raw material dependency, geopolitical instability, and potential quality failures.
• Strategic sourcing necessitates a dual-sourcing approach, thorough IP due diligence, and long-term supply agreements to ensure continuity and mitigate risks.

FREQUENTLY ASKED QUESTIONS

1. When is Vismodegib API likely to become available from multiple generic manufacturers? Availability from multiple generic manufacturers will depend on the expiration of key patents and any successful patent challenges. Companies often begin API development and regulatory filings in anticipation of patent expiry, with commercial API supply becoming available shortly thereafter. Specific patent expiry dates for Vismodegib are [refer to patent section and advise verification].

2. What is the typical lead time for sourcing Vismodegib API from a qualified manufacturer? Lead times can vary significantly based on the supplier's current production schedule, the volume required, and whether the API is a standard catalog item or requires custom campaign manufacturing. For a specialized API like Vismodegib, lead times can range from 3-6 months for established, ongoing production, and potentially longer for new manufacturing campaigns.

3. Can Vismodegib API be manufactured using a different synthetic route than that used by the originator? Yes, it is possible to develop alternative synthetic routes. However, any new process must not infringe on existing process patents and must still yield API that meets all regulatory specifications, including purity and polymorphic form. Developing and validating a novel synthetic route is a complex and time-consuming undertaking.

4. How can a drug product manufacturer ensure the quality and authenticity of Vismodegib API? Ensuring quality and authenticity involves a multi-faceted approach: thorough supplier qualification audits, reviewing DMF/ASMF filings, establishing robust quality agreements, testing incoming API lots for identity, purity, and critical quality attributes, and implementing supply chain security measures to prevent counterfeiting.

5. What are the typical cost drivers for Vismodegib API? Cost drivers include the complexity of the multi-step synthesis, the cost of specialized raw materials and reagents, the stringent quality control and analytical testing required, cGMP compliance overhead, regulatory filing costs (DMF/ASMF), and the scale of production. Limited supplier competition can also influence pricing.

CITATIONS

[1] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA Website]

[2] European Medicines Agency. (n.d.). Information on Medicines. Retrieved from [EMA Website]

[3] Genentech, Inc. (n.d.). Erivedge Prescribing Information. Retrieved from [Genentech/Roche Website or FDA Label Repository]

[4] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Website]

[5] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from [EPO Website]

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website]